(CercleFinance.com) – Bristol Myers Squibb presents new interim pooled safety and long-term metabolic outcomes data from the EMERGENT program evaluating KarXT in schizophrenia at the 2024 Annual Meeting of the International Society for Schizophrenia Research.
KarXT demonstrated a favorable long-term metabolic profile where most patients experienced stability or improvement in metabolic parameters over the 52 weeks of treatment.
The majority of patients (65%) experienced weight loss during the trial, with an average weight reduction of 2.6 kg observed at one year.
Data show no significant prolactin-related or clinically meaningful changes in Movement Disorders Scale scores over 52 weeks
“These long-term safety and metabolism results from the EMERGENT program are extremely encouraging, as they allow us to better understand the tolerability profile of KarXT in people with schizophrenia,” said Roland Chen, MD, vice -senior president and head of immunology, cardiovascular disease and neuroscience development at Bristol Myers Squibb.
‘It is promising that over the course of a year of treatment, KarXT was not associated with serious side effects, particularly weight gain and metabolic dysfunction, as well as extrapyramidal symptoms, which which highlights its potential to provide a meaningful and differentiated option for people with schizophrenia. ‘
Copyright (c) 2024 CercleFinance.com. All rights reserved.